Skip to main content
main-content

01.12.2016 | Research | Ausgabe 1/2016 Open Access

Systematic Reviews 1/2016

Chinese herbal medicine for the treatment of primary hypertension: a methodology overview of systematic reviews

Zeitschrift:
Systematic Reviews > Ausgabe 1/2016
Autoren:
Zhao Xinke, Li Yingdong, Feng Mingxia, Liu Kai, Chen Kaibing, Lu Yuqing, Sun Shaobo, Song Peng, Liu Bin
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​s13643-016-0353-y) contains supplementary material, which is available to authorized users.

Abstract

Background

Chinese herbal medicine has been used to treat hypertension in China and East Asia since centuries. In this study, we conduct an overview of systematic reviews of Chinese herbal medicine in the treatment of primary hypertension to 1) summarize the conclusions of these reviews, 2) evaluate the methodological quality of these reviews, and 3) rate the confidence in the effect on each outcome.

Methods

We comprehensively searched six databases to retrieve systematic reviews of Chinese herbal medicine for primary hypertension from inception to December 31, 2015. We used AMSTAR to evaluate the methodological quality of included reviews, and we classified the quality of evidence for each outcome in included reviews using the GRADE approach.

Results

A total of 12 systematic reviews with 31 outcomes were included, among which 11 systematic reviews focus on the therapeutic effect of Chinese herbal medicine combined with conventional medicine or simple Chinese herbal medicine versus simple conventional medicine. Among the 11 items of AMSTAR, the lowest quality was “providing a priori design” item, none review conformed to this item, the next was “stating the conflict of interest” item, only three reviews conformed to this item. Five reviews scored less than seven in AMSTAR, which means that the overall methodological quality was fairly poor. For GRADE, of the 31 outcomes, the quality of evidence was high in none (0 %), moderate in three (10 %), low in 19 (61 %), and very low in nine (29 %). Of the five downgrading factors, risk of bias (100 %) was the most common downgrading factor in the included reviews, followed by imprecision (42 %), inconsistency (39 %), publication bias (39 %), and indirectness (0 %).

Conclusions

The methodological quality of systematic reviews about Chinese herbal medicine for primary hypertension is fairly poor, and the quality of evidence level is low. Physicians should be cautious when applying the interventions in these reviews for primary hypertension patients in clinical practice.
Zusatzmaterial
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2016

Systematic Reviews 1/2016 Zur Ausgabe